Pomalyst

Chemical Namepomalidomide
Dosage FormCapsules (oral; 1mg, 2mg, 3mg, and 4mg)
Drug ClassAntineoplastics
SystemBlood
CompanyCelgene Corporation
Approval Year2013

Indication

  • In combination with dexamethasone, indicated for the treatment of adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
  • For the treatment of adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative.
Last updated on 4/29/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Pomalyst (pomalidomide) Prescribing Information2013Celgene Corporation Summit, NJ
Document TitleYearSource
Multiple myeloma, version 3.2021.2020Journal of the National Comprehensive Cancer Network
Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.2017Annals of Oncology